ACST Stock – (NASDAQ: ACST) is providing an update on the use
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the usage of the “at the market” equity of its providing program.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering system under which Acasti might issue and sell from time to time its everyday shares having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares had been sold at prevailing market rates averaging US$1.0747 a share. No securities had been marketed through the facilities of the TSXV or maybe, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will supply the Company with more freedom in its ongoing review process to explore as well as evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription medications making use of OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of safety and efficacy for lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for clients with severe HTG.
Forward Looking Statements – ACST Stock
Statements in that press release that are not statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements involve known and unknown risks, uncertainties, and other unknown elements that could cause the particular outcomes of Acasti to be materially different from historical success and even as a result of any later outcomes expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, readers are actually urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the particular date of this press release. Forward-looking statements in that press release include, but aren’t confined to, info or statements concerning Acasti’s strategy, future operations as well as its review of strategic options.
The forward looking statements contained in this specific press release are expressly qualified in their entirety by this alerting declaration, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor aisle of Acasti’s website at www.acastipharma.com. All forward-looking claims in this press release are produced as of the day of this press release.
ACST Stock – Acasti doesn’t undertake to update any such forward-looking statements whether as a result of information that is new , future events or perhaps otherwise, except as called for by law. The forward-looking statements contained herein are also subject typically to assumptions and risks as well as uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage